Asperjinone, a Nor-Neolignan, and Terrein, a Suppressor of ABCG2-Expressing Breast Cancer Cells, from Thermophilic Aspergillus terreus

Citations Over TimeTop 10% of 2012 papers

Abstract

Breast cancer cells express ABCG2 transporters, which mediate multidrug resistance. Discovering a novel compound that can suppress ABCG2 expression and restore drug sensitivity could be the key to improving breast cancer therapeutics. In the current work, one new nor-neolignan, asperjinone (1), as well as 12 other known compounds, was isolated from Aspergillus terreus. The structure of the new isolate was determined by spectroscopic methods. Among these isolates, terrein (2) displayed strong cytotoxicity against breast cancer MCF-7 cells. Treatment with terrein (2) significantly suppressed growth of ABCG2-expressing breast cancer cells. This suppressive effect was achieved by inducing apoptosis via activating the caspase-7 pathway and inhibiting the Akt signaling pathway, which led to a decrease in ABCG2-expressing cells and a reduction in the side-population phenotype.

Related Papers

• → Breast cancer, side population cells and ABCG2 expression(2012)123 cited
• → Secalonic acid D reduced the percentage of side populations by down-regulating the expression of ABCG2(2013)46 cited
• → Clinically relevant interactions of anti-apoptotic Bcl-2 protein inhibitors with ABC transporters.(2017)9 cited
• → Relevance of Transporters in Clinical Studies(2018)